Skip to main content

What the FDA labels say about taking them together

Letermovir and rifabutin

Letermovir's FDA label of January 14, 2026 names rifabutin in its drug interactions section; the rifabutin label PlainMeds reads does not name letermovir. The letermovir label: “Co-administration of PREVYMIS and rifabutin is not recommended due to potential for loss of efficacy of PREVYMIS.”

Check it at the source: the letermovir FDA label on DailyMed (effective January 14, 2026, Merck Sharp & Dohme LLC); the rifabutin FDA label on DailyMed (effective September 1, 2026, REMEDYREPACK INC.).

What does the letermovir label say about rifabutin?

Letermovir label, drug interactions

Concomitant Drug Class and/or Clearance Pathway/Drug Name: rifabutin; Effect on Concentration ↓ =decrease, ↑ =increase: ↓ letermovir; Clinical Comments: Co-administration of PREVYMIS and rifabutin is not recommended due to potential for loss of efficacy of PREVYMIS.

Source: FDA drug label (PREVYMIS), Merck Sharp & Dohme LLC, effective January 14, 2026 (SPL set 1b49df80-be4f-47e0-a0b7-123f3e69395b), via openFDA; the full label on DailyMed

What does the rifabutin label say about letermovir?

Rifabutin's label (effective September 1, 2026) does not name letermovir in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Rifabutin), NDA050689 (Pfizer), as published by REMEDYREPACK INC., effective September 1, 2026 (SPL set 25a60937-cbbe-4a50-994f-2ce15203f589), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Letermovir generic labelers
4Rifabutin generic labelers
LetermovirRifabutin
Labeled forn/an/a
Boxed warningNoNo
Pharmacy cost (NADAC)n/a$8.14 per capsule 150 mg capsule
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?